Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Procept Biorobotics Corp (PRCT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: PRCT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $66.22
1 Year Target Price $66.22
| 6 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -17.34% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.23B USD | Price to earnings Ratio - | 1Y Target Price 66.22 |
Price to earnings Ratio - | 1Y Target Price 66.22 | ||
Volume (30-day avg) 10 | Beta 1.04 | 52 Weeks Range 37.12 - 103.81 | Updated Date 08/15/2025 |
52 Weeks Range 37.12 - 103.81 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.54 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-07-30 | When Before Market | Estimate -0.4125 | Actual -0.35 |
Profitability
Profit Margin -30.6% | Operating Margin (TTM) -28.02% |
Management Effectiveness
Return on Assets (TTM) -12.93% | Return on Equity (TTM) -26.4% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2008763952 | Price to Sales(TTM) 8.12 |
Enterprise Value 2008763952 | Price to Sales(TTM) 8.12 | ||
Enterprise Value to Revenue 7.31 | Enterprise Value to EBITDA -24.58 | Shares Outstanding 55635900 | Shares Floating 53512317 |
Shares Outstanding 55635900 | Shares Floating 53512317 | ||
Percent Insiders 4.19 | Percent Institutions 100.08 |
Upturn AI SWOT
Procept Biorobotics Corp
Company Overview
History and Background
Procept BioRobotics is a surgical robotics company focused on advancing patient care by developing, manufacturing, and marketing minimally invasive surgical solutions to treat benign prostatic hyperplasia (BPH). The company was founded in 2008 and went public in 2021. Its AquaBeam Robotic System for Aquablation therapy is its primary offering.
Core Business Areas
- Surgical Robotics: Development, manufacturing, and marketing of surgical robotic systems and related disposable products, focusing on urology.
- Aquablation Therapy: Providing Aquablation therapy, a minimally invasive treatment for BPH that utilizes a heat-free waterjet delivered robotically to resect prostate tissue.
Leadership and Structure
The leadership team includes key executives in roles such as CEO, CFO, and medical officer. The organizational structure consists of departments focused on research and development, manufacturing, sales and marketing, and clinical support.
Top Products and Market Share
Key Offerings
- AquaBeam Robotic System: The AquaBeam Robotic System delivers Aquablation therapy for the treatment of BPH. The system uses a robotically controlled waterjet to precisely remove prostate tissue. Market share for Aquablation is still growing within the broader BPH treatment market, competing with traditional TURP, laser therapies, and medications. Exact market share figures are constantly changing but it has had significant growth. Competitors include Boston Scientific, Olympus, Teleflex.
Market Dynamics
Industry Overview
The surgical robotics market is experiencing significant growth driven by advancements in technology and a growing demand for minimally invasive procedures. The BPH treatment market is competitive with a mix of established and emerging technologies.
Positioning
Procept BioRobotics is positioned as an innovator in the BPH treatment market with its Aquablation therapy offering a unique and minimally invasive approach. Their competitive advantage lies in the precision and safety of robotic-assisted waterjet resection.
Total Addressable Market (TAM)
The TAM for BPH treatment is estimated to be in the billions of dollars annually. Procept BioRobotics is positioned to capture a significant portion of this market as Aquablation gains wider adoption.
Upturn SWOT Analysis
Strengths
- Innovative Aquablation technology
- Minimally invasive procedure
- Robotic precision and safety
- Growing clinical evidence supporting efficacy
Weaknesses
- Relatively new technology with limited long-term data
- Higher initial cost compared to traditional BPH treatments
- Requires specialized training for surgeons
- Limited brand recognition compared to established competitors
Opportunities
- Expanding market adoption of Aquablation therapy
- Increasing awareness and education among patients and physicians
- Developing new applications for Aquablation technology
- Partnerships with hospitals and medical centers
Threats
- Competition from established BPH treatment methods
- Reimbursement challenges from insurance providers
- Technological advancements from competitors
- Potential for adverse events or complications
Competitors and Market Share
Key Competitors
- Boston Scientific (BSX)
- Olympus (OCPNY)
- Teleflex (TFX)
Competitive Landscape
Procept BioRobotics offers a novel approach to BPH treatment with its Aquablation therapy. Its competitive advantage lies in the precision and safety of robotic-assisted waterjet resection, but faces competition from larger, established players with a wider range of BPH treatment options. Their smaller scale gives them less competitive advantages, although their growth makes them attractive.
Growth Trajectory and Initiatives
Historical Growth: Procept BioRobotics has experienced significant revenue growth in recent years driven by increased adoption of Aquablation therapy.
Future Projections: Analyst estimates project continued growth for Procept BioRobotics as Aquablation gains wider acceptance and expands its market share. Check analyst reports from major firms.
Recent Initiatives: Recent initiatives include expanding its sales force, increasing marketing efforts, and conducting clinical trials to further validate the efficacy of Aquablation therapy.
Summary
Procept BioRobotics is an innovative company in the BPH treatment market with its unique Aquablation technology and strong growth. The company's strengths lie in its innovative technology and minimally invasive approach, but it faces challenges related to limited brand recognition and competition from established players. The company should focus on increasing awareness and education, expanding its market presence, and continuing to develop its technology. With more long term information, the company can become more valuable.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Procept Biorobotics Corp
Exchange NASDAQ | Headquaters San Jose, CA, United States | ||
IPO Launch date 2021-09-15 | President, CEO & Director Dr. Reza Zadno Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 756 | |
Full time employees 756 | |||
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. It also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.